Julian Jenkins

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. doi request reprint Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers
    Gemma Matthys
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    J Clin Pharmacol 51:301-8. 2011
  2. ncbi request reprint Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist
    Julian M Jenkins
    GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA
    Blood 109:4739-41. 2007
  3. doi request reprint Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis
    Julian Jenkins
    Oncology Medicine Development Center, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA
    Eur J Clin Pharmacol 66:67-76. 2010

Detail Information

Publications3

  1. doi request reprint Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers
    Gemma Matthys
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    J Clin Pharmacol 51:301-8. 2011
    ..Eltrombopag pharmacokinetics and platelet response were dose-dependent, and doses up to 200 mg/d were well tolerated, with safety profiles similar to placebo...
  2. ncbi request reprint Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist
    Julian M Jenkins
    GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA
    Blood 109:4739-41. 2007
    ..These observations indicate that eltrombopag is a once-daily, oral TpoR agonist with demonstrated thrombopoietic activity in human subjects, encouraging further studies in patients with thrombocytopenia...
  3. doi request reprint Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis
    Julian Jenkins
    Oncology Medicine Development Center, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA
    Eur J Clin Pharmacol 66:67-76. 2010
    ..Therefore the potential for eltrombopag to interact with cytochrome P450 activity was investigated...